Articles tagged with Cell Therapies
Researchers successfully reprogrammed non-controllers' CD8+ T cells to acquire properties of natural HIV controllers, enabling them to suppress viral load and survive without exhaustion. This breakthrough could lead to a cell therapy strategy for achieving HIV remission, with potential applications in cancer treatments.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
José McFaline-Figueroa, a genomicist at Columbia University, has received a three-year NSF CAREER Award to investigate how cancer cells respond to anti-cancer therapy. His research aims to understand the molecular changes induced in aggressive cancer cells after exposure to treatment and how these changes alter response to treatment.
Researchers at Massachusetts General Hospital have developed a novel CAR T-cell construct that targets acute myeloid leukemia (AML) effectively. The combination of drug therapy and engineering approaches enhanced the treatment's ability to adhere to tumor cells, overcoming previous difficulties with antigen targeting.
Researchers at St. Jude Children's Research Hospital found that EGFR inhibitor treatment can target and kill persistent cancer cells in rhabdomyosarcoma, a type of soft tissue cancer common in children. The study's results support a new clinical trial strategy for treating the disease.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
Researchers have discovered that vesicles from human heart cells can repair damaged tissue and prevent lethal heart rhythm disorders. The treatment, using cardiosphere-derived cells (CDCs) and their secreted exosomes, showed improved heart rhythms and reduced scarring in animal models.
Researchers developed a virus that infects cancer cells, killing them while sending signals to nearby uninfected cells for viral attack. This approach shrinks tumors and enhances cancer-killing efficacy in various models, including pancreatic and ovarian cancers.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Researchers discovered that obesity changes molecular underpinnings of allergic inflammation in both mice and humans. The treatment in obese mice makes their skin worse instead of healing, but a specific drug can 'de-fatten' obese mice without changing body weight.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers created cortical organoids from patients' skin cells, mimicking focal cortical dysplasia and identifying mechanisms involved in its emergence. The model can be used to screen existing medications for patients with severe epilepsy.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
A new study led by Kelly Monaghan at West Virginia University suggests that interrupting the immune response may improve multiple sclerosis outcomes. The researchers found that targeting a specific protein called CCL17 can prevent the disease from attacking the central nervous system, leading to milder symptoms and delayed paralysis.
Researchers at the University of Houston have developed a novel technology to monitor membrane protein trafficking in real-time using bioluminescence. This allows for the study of cellular processes and drug development for heart disease, metabolic disorders, cancer, infectious diseases, COVID-19, and others.
A new CNIC study warns that mitochondrial therapeutic interventions can cause damage due to the mixing of mitochondrial DNAs from two distinct origins. This can lead to medium- and long-term health issues, including heart failure, pulmonary hypertension, and muscle loss.
Researchers identified key differences in metabolic processes between brain and spinal cord oligodendrocytes, which could lead to new therapeutic treatments for neurodegenerative diseases. The study also found that targeting a specific cell protein may enhance cholesterol and myelin production.
A clinical trial at UC Davis Health showed that cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy, stopping deterioration of upper limb and heart functions. The therapy appears to be safe and effective in improving skeletal muscle and cardiac function.
Researchers at Cedars-Sinai have identified a potential new therapy for COVID-19, created by reengineered human skin cells. The substance, dubbed ASTEX, stops SARS-CoV-2 from reproducing itself and protects infected cells in human lung cell samples.
Researchers at the Salk Institute successfully reversed aging signs in middle-aged and elderly mice using a cellular rejuvenation approach. The treatment, which involves reprogramming cells with four specific molecules, restored youthful epigenetic patterns and improved tissue function without increasing cancer risk.
Researchers uncover the pleiotropic functions of hnRNPK in regulating skeletal muscle cell differentiation, including inhibition of myoblast differentiation and suppression of genes involved in endoplasmic reticulum stress. The study suggests that targeting hnRNPK could be a potential therapeutic strategy for treating human disorders.
Scientists at the Max Planck Institute of Biochemistry have discovered a new subtype of acute myeloid leukemia (AML) characterized by high amounts of mitochondrial proteins and altered mitochondrial metabolism. This subtype, called Mito-AML, shows clinical resistance to chemotherapy and can be effectively combated with inhibitors again...
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
The article suggests a potential treatment option for COVID-19 by targeting SARS-CoV-2's interaction with ACE2 receptors. Combining DPP4 inhibitors and spironolactone may mitigate COVID-19 complications and infections without adverse side effects.
A team of researchers at MedUni Vienna's Center for Physiology and Pharmacology has discovered a key building block in immune cells that promotes immunotolerance and prevents T-cell attacks on the body's own tissues. The study suggests a potential new cell-based therapeutic approach to slow down autoimmune disease progression.
Codiak BioSciences' exoASO-STAT6 demonstrates potent anti-tumor efficacy by reprogramming tumor-associated macrophages to an M1 phenotype, showing promise as a monotherapy candidate for hepatocellular carcinomas and other cancers. The company plans to initiate Phase 1 clinical trials in the first half of 2022.
Researchers found that repetitive exposure to environmental hypoxia prevented memory loss and reversed impairments in nerve-to-nerve communication. Adult offspring also inherited this protection against dementia.
Paczesny will explore biomarkers and a new type of immune cell to identify and regulate acute lung injury after BMT. She aims to improve understanding of signaling mechanisms in lung injury after BMT, particularly as they relate to idiopathic pneumonia syndrome.
Patients with severe coronary artery calcium have a significantly increased risk of major adverse cardiovascular events during thoracic radiation therapy for non-small cell lung cancer. The study found that patients with severe coronary artery calcium had a 21.4 times increased risk compared to those with no coronary artery calcium.
Researchers have developed a new system called Species Agnostic Nanoparticle Delivery Screening (SANDS) that improves the screening process for drug-delivering nanoparticles. SANDS allows for simultaneous testing of nanoparticles in mouse, primate, and human cells, enabling more accurate predictions of delivery in humans.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers at Gladstone Institutes and UC San Francisco have developed a CRISPR activation method that allows them to activate genes in human immune cells, revealing key regulators of cytokine production. This breakthrough accelerates immunotherapy research and may lead to more powerful cancer treatments.
Scientists at Cold Spring Harbor Laboratory have developed a way to interfere with the energy pathway that allows liver cancer to grow and spread by targeting the pyruvate kinase protein. This approach uses antisense oligonucleotides, which reduce tumor development in mouse models, offering a potential treatment for liver cancer.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers at Northwestern University have developed a novel microfluidic device that can efficiently harvest and sort tumor-eating immune cells from tumors. This technology has shown dramatic results in shrinking tumors in mice compared to traditional methods.
A team of researchers at Harvard's Wyss Institute and ETH Zurich have developed a computational approach to identify genomic safe harbors (GSHs) with high potential for safe insertion of therapeutic genes. The study validated two GSH sites in adoptive T cell therapies and in vivo gene therapies for skin diseases.
The new BD CellView Image Technology enables high-speed sorting of individual cells based on detailed microscopic analysis, accelerating discovery research in immunology, cell biology, and genomics. This technology has the potential to unlock new cell-based therapeutic discoveries and transform various fields of biomedical research.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.
Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
Researchers at A*STAR's Institute of Molecular and Cell Biology have discovered a novel protein therapy using Agrin to promote wound healing and repair. The study found that timely induction or exogenous supplementation of Agrin accelerates the healing process, preserving the mechanical architecture of injured skin layers.
A team of researchers has developed a Dynamic Sampling Platform to analyze cells in real-time, overcoming the time-consuming and expensive process of biomanufacturing. The platform provides insight into cell behavior and biochemical information needed for process control, potentially lowering the cost of cell therapies.
Researchers create a porous microneedle to deliver CAR T cells into solid tumors, improving anti-tumor effects. The strategy showed enhanced tumor infiltration and amplification of CAR T cells in melanoma models.
Researchers used next-generation DNA sequencing to detect residual disease in patients treated with CAR-T therapy for acute lymphoblastic leukemia. The study found that DNA sequencing was more sensitive and accurate than flow cytometry in predicting relapse, enabling earlier intervention.
Recent clinical trials showed promising results with cardiosphere-derived cells, improving heart parameters in patients with Duchenne muscular dystrophy. Researchers investigate using cell-derived products like exosomes to boost endogenous repair pathways, while aiming to reverse cardiomyocytes' proliferation limitations.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
A fasting-mimicking diet was found to be safe and biologically active in cancer patients, with potential benefits for modulation of metabolism and enhancement of antitumor immunity. The study demonstrated significant reductions in blood glucose and growth factor concentrations, as well as enhancements in intratumor T-cell infiltration.
A new study led by University of Minnesota Medical School researcher Xavier Revelo found that macrophages play a role in protecting the heart after injury. The research team discovered a large increase in cardiac macrophages early in response to a cardiac injury similar to high blood pressure.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.